Cargando…

Tumor-Associated Macrophages: Key Players in Triple-Negative Breast Cancer

Triple negative breast cancer (TNBC) refers to the subtype of breast cancer which is negative for ER, PR, and HER-2 receptors. Tumor-associated macrophages (TAMs) refer to the leukocyte infiltrating tumor, derived from circulating blood mononuclear cells and differentiating into macrophages after ex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qiu, Xia, Zhao, Tianjiao, Luo, Ran, Qiu, Ran, Li, Zhaoming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882594/ https://www.ncbi.nlm.nih.gov/pubmed/35237507 http://dx.doi.org/10.3389/fonc.2022.772615

Ejemplares similares

Key Players in Choline Metabolic Reprograming in Triple-Negative Breast Cancer
por: Iorio, Egidio, et al.
Publicado: (2016)

Tumor Microenvironment: Key Players in Triple Negative Breast Cancer Immunomodulation
por: Zheng, Hongmei, et al.
Publicado: (2021)

Identification of Key Genes Affecting the Tumor Microenvironment and Prognosis of Triple-Negative Breast Cancer
por: Yi, Jiarong, et al.
Publicado: (2021)

Prospects of Immunotherapy for Triple-Negative Breast Cancer
por: Qiu, Dan, et al.
Publicado: (2022)

A pyroptosis-associated gene risk model for predicting the prognosis of triple-negative breast cancer
por: Qiu, Pengjun, et al.
Publicado: (2022)

Identification of Potential Key Genes Associated With the Pathogenesis, Metastasis, and Prognosis of Triple-Negative Breast Cancer on the Basis of Integrated Bioinformatics Analysis
por: Zhao, Bin, et al.
Publicado: (2020)

Identification of immunosuppressive signature subtypes and prognostic risk signatures in triple-negative breast cancer
por: Ding, Ran, et al.
Publicado: (2023)

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
por: Luo, Chenyi, et al.
Publicado: (2022)

The Heparan Sulfate Binding Peptide in Tumor Progression of Triple-Negative Breast Cancer
por: Melo, Carina Mucciolo, et al.
Publicado: (2021)

Editorial: Triple-negative breast cancer: Heterogeneity, tumor microenvironment and targeted therapy
por: Deng, Xiyun, et al.
Publicado: (2022)

ASMT Regulates Tumor Metastasis Through the Circadian Clock System in Triple-Negative Breast Cancer
por: Xie, FenFen, et al.
Publicado: (2020)

Diagnostic Value of Radiomics Analysis in Contrast-Enhanced Spectral Mammography for Identifying Triple-Negative Breast Cancer
por: Zhang, Yongxia, et al.
Publicado: (2021)

Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Sun, Xiangyu, et al.
Publicado: (2020)

Nanomaterial Technology and Triple Negative Breast Cancer
por: Hou, Kai, et al.
Publicado: (2022)

Non-Coding RNAs Associated With Radioresistance in Triple-Negative Breast Cancer
por: Aranza-Martínez, Alberto, et al.
Publicado: (2021)

Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer
por: Schreier, Ashley, et al.
Publicado: (2023)

Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells Through CDK7 Inhibition
por: Peng, Jingyu, et al.
Publicado: (2021)

Lactate Metabolism and Immune Modulation in Breast Cancer: A Focused Review on Triple Negative Breast Tumors
por: Naik, Adviti, et al.
Publicado: (2020)

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
por: Li, Ying, et al.
Publicado: (2021)

Rewiring of the Endocrine Network in Triple-Negative Breast Cancer
por: Li, Kaixuan, et al.
Publicado: (2022)

Unraveling Heterogeneity of Tumor Cells and Microenvironment and Its Clinical Implications for Triple Negative Breast Cancer
por: Jiang, Ke, et al.
Publicado: (2021)

Current Management Strategies in Breast Cancer by Targeting Key Altered Molecular Players
por: Ali, Shazia, et al.
Publicado: (2016)

Ferroptosis and triple-negative breast cancer: Potential therapeutic targets
por: Xu, Na, et al.
Publicado: (2022)

Triple-Negative Breast Cancer Comparison With Canine Mammary Tumors From Light Microscopy to Molecular Pathology
por: Amirkhani Namagerdi, Asadoor, et al.
Publicado: (2020)

LAG-3(+) tumor-infiltrating lymphocytes ameliorates overall survival in triple-negative breast cancer patients
por: Hu, Guoming, et al.
Publicado: (2023)

Multiomics technologies for comprehensive tumor microenvironment analysis in triple-negative breast cancer under neoadjuvant chemotherapy
por: Wang, Gang, et al.
Publicado: (2023)

SENP3 promotes tumor progression and is a novel prognostic biomarker in triple-negative breast cancer
por: Zhu, Youzhi, et al.
Publicado: (2023)

Prognostic Value of Ki-67 in Patients With Resected Triple-Negative Breast Cancer: A Meta-Analysis
por: Wu, Qiang, et al.
Publicado: (2019)

Identification of a Hypoxia-Related Molecular Classification and Hypoxic Tumor Microenvironment Signature for Predicting the Prognosis of Patients with Triple-Negative Breast Cancer
por: Sun, Xiaoli, et al.
Publicado: (2021)

Sialic Acid Metabolism: A Key Player in Breast Cancer Metastasis Revealed by Metabolomics
por: Teoh, Shao Thing, et al.
Publicado: (2018)

Identification of MTHFD2 as a prognostic biomarker and ferroptosis regulator in triple-negative breast cancer
por: Zhang, Hao, et al.
Publicado: (2023)

Capecitabine-based chemotherapy in early-stage triple-negative breast cancer: a meta-analysis
por: Bai, Jie, et al.
Publicado: (2023)

WFDC21P promotes triple-negative breast cancer proliferation and migration through WFDC21P/miR-628/SMAD3 axis
por: Wei, Yu-Bo, et al.
Publicado: (2022)

ERK5 Is Required for Tumor Growth and Maintenance Through Regulation of the Extracellular Matrix in Triple Negative Breast Cancer
por: Hoang, Van T., et al.
Publicado: (2020)

Correlation Between Mammographic Radiomics Features and the Level of Tumor-Infiltrating Lymphocytes in Patients With Triple-Negative Breast Cancer
por: Yu, Hongwei, et al.
Publicado: (2020)

Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: da Silva, Jesse Lopes, et al.
Publicado: (2021)

Hyperoxygenation as a Therapeutic Supplement for Treatment of Triple Negative Breast Cancer
por: Mast, Jesse M., et al.
Publicado: (2018)

Biological Landscape of Triple Negative Breast Cancers Expressing CTLA-4
por: Navarrete-Bernal, María G. C., et al.
Publicado: (2020)

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
por: Han, Ye, et al.
Publicado: (2020)

Nomogram for Predicting Lymph Node Involvement in Triple-Negative Breast Cancer
por: Cui, Xiang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rqi5cldcr40u13fkmqiei49fkf